Assenagon Asset Management S.A. Purchases Shares of 40,243 Thermo Fisher Scientific Inc (TMO)

Assenagon Asset Management S.A. bought a new stake in Thermo Fisher Scientific Inc (NYSE:TMO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,243 shares of the medical research company’s stock, valued at approximately $7,614,000.

Other institutional investors also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in shares of Thermo Fisher Scientific by 57.0% in the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after buying an additional 16,308 shares in the last quarter. BB&T Securities LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.4% in the 1st quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock valued at $13,798,000 after buying an additional 3,819 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after buying an additional 977 shares in the last quarter. Mitchell Capital Management Co. boosted its holdings in shares of Thermo Fisher Scientific by 40.3% in the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after buying an additional 12,910 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after buying an additional 5,213 shares in the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares in the company, valued at approximately $6,790,226.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by insiders.

TMO has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a report on Thursday, September 7th. Morgan Stanley restated an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Cowen and Company restated an “outperform” rating and issued a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Finally, Bank of America Corporation restated a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $205.71.

WARNING: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/14/assenagon-asset-management-s-a-purchases-shares-of-40243-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at $188.21 on Tuesday. The company has a market cap of $74,657.32, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 EPS. sell-side analysts expect that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.19%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply